CORT125134: Phase I/II started

Corcept began an open-label, U.S. Phase I/II trial to evaluate once-daily oral CORT125134 plus IV Abraxane nab-paclitaxel in 28-day cycles in about 82 patients. A dose-escalation phase in up to 42 pa...